The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), as an adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. The approval decision is expected by November 30, 2026. Phase III trial data showed giredestrant reduced the risk of invasive disease recurrence or death by 30% compared to standard endocrine therapy, marking the first major advance in adjuvant endocrine therapy in over 20 years. Giredestrant was well tolerated with fewer treatment discontinuations, potentially setting a new standard of care for over 90% of early-stage ER-positive breast cancer patients.
dsm-firmenich announced ongoing progress in its share repurchase program, buying back 184,000 shares between May 25-29, 2026, at an average price of €72.36 per share, totaling €13.3 million. This is part of a larger €540 million buyback initiated in ...
Sika has appointed Philipp Irniger as the new Head of Construction and member of Group Management, succeeding Ivo Schädler who will retire in March 2027. Irniger brings extensive international experience and will lead Sika's global construction busin...
Cheetah Net Supply Chain Service Inc. (CTNT) shares surged 71.04% in after-hours trading following the completion of its acquisition of Super International Trading Limited, a Hong Kong-based industrial equipment trading company. The deal, valued at a...
Virginia Governor Abigail Spanberger signed House Bill 655 and Senate Bill 346, reforming zoning laws to allow manufactured homes in areas where site-built homes are permitted. The laws prevent local governments from imposing stricter rules on manufa...
SEALSQ has increased its ownership in Wecan Group to a majority stake, following an initial 28% investment a year ago, and is investing CHF 5 million to accelerate the development of AI-powered compliance and post-quantum security solutions for globa...
